Clinical Trial Update: A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

A long-term extension study stemming from late-phase II testing of SPM 962 in advanced Parkinson's disease; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SPM 962

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-03-19